ProShare Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

ProShare Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,484	Closed	-$78K	–	2233
2022 Q1	$78K	Sell	11,484 -2,933	-20%	-$20.9K	﹤0.01%	2072
2021 Q4	$120K	Sell	14,417 -753	-5%	-$6.2K	﹤0.01%	2166
2021 Q3	$113K	Sell	15,170 -2,584	-15%	-$16K	﹤0.01%	1900
2021 Q2	$121K	Buy	17,754 +6,882	+63%	+$57.2K	﹤0.01%	2266
2021 Q1	$112K	Buy	+10,872	New	+$119K	﹤0.01%	2152
2018 Q4	–	Sell	-15,233	Closed	-$99K	–	1738
2018 Q3	$99K	Sell	15,233 -496	-3%	-$3.69K	﹤0.01%	1681
2018 Q2	$120K	Sell	15,729 -1,030	-6%	-$14.9K	﹤0.01%	1689
2018 Q1	$375K	Sell	16,759 -2,762	-14%	-$61.3K	﹤0.01%	1218
2017 Q4	$249K	Buy	+19,521	New	+$287K	﹤0.01%	1518

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

ProShare Advisors's JNCE Position: Q2 2022 in Review

ProShare Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 11,484 shares — an estimated $78K sold.

ProShare Advisors first reported a position in JNCE in Q4 2017 and held it in 9 quarters. The position peaked at $375K in Q1 2018. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

ProShare Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 11,484 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $78K.
ProShare Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
ProShare Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $375K in Q1 2018.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.